Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study

References

• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019–5032.
   PubMed Web of Science ®Google Scholar
• Ellin F, Landstrom J, Jerkeman M, et al. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124:1570–1577.
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D. International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–4130.
   PubMed Web of Science ®Google Scholar
• Arrowsmith ER, Macon WR, Kinney MC, et al. Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification. Leuk Lymphoma. 2003;44:241–249.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15:1467–1475.
   PubMed Web of Science ®Google Scholar
• Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. JCO. 2013;31:1970–1976.
   PubMed Web of Science ®Google Scholar
• d'Amore F, Gaulard P, Trumper L, et al. Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v108–v115.
   PubMed Web of Science ®Google Scholar
• El-Galaly TC, Mylam KJ, Bogsted M, et al. Role of routine imaging in detecting recurrent lymphoma: a review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. Am J Hematol. 2014;89:575–580.
   PubMed Web of Science ®Google Scholar
• Thompson CA, Ghesquieres H, Maurer MJ, et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol. 2014;32:3506–3512.
   PubMed Web of Science ®Google Scholar
• El-Galaly TC, Jakobsen LH, Hutchings M, et al. Routine imaging for diffuse large B-cell lymphoma in first complete remission does not improve post-treatment survival: a Danish-Swedish population-based study. JCO. 2015;33:3993–3998.
   PubMed Web of Science ®Google Scholar
• Jakobsen LH, Hutchings M, de Nully Brown P, et al. No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study. Br J Haematol. 2016;173:236–244.
   PubMed Web of Science ®Google Scholar
• Jerkeman M. Swedish Lymphoma Registry 2000–2012 (Regional Cancer Centre South, Lund, Sweden); 2014.
   Google Scholar
• De Nully Brown PJJ, Munksgaard L. Annual report of the Danish Lymphoma Group (2011); 2012.
   Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. JCO. 2014;32:3059–3068.
   PubMed Web of Science ®Google Scholar
• Relander TSL. Nationella riktlinjer för behandling av T-cellslymfom; 2014.
   Google Scholar
• Aalen O. Nonparametric estimation of partial transition probabilities in multiple decrement models. Ann Statist. 1978;6:534–545.
   Web of Science ®Google Scholar
• Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist. 1988;16:1141–1154.
   Web of Science ®Google Scholar
• Verheul HA, Dekker E, Bossuyt P, et al. Background mortality in clinical survival studies. Lancet. 1993;341:872–875.
   PubMed Web of Science ®Google Scholar
• Breslow NE, Lubin JH, Marek P, et al. Multiplicative models and cohort analysis. J Am Statist Assoc. 1983;78:1–12.
   Web of Science ®Google Scholar
• Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991;9:191–192.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Ghesquieres H, Jais JP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32:1066–1073.
   PubMed Web of Science ®Google Scholar
• Hapgood G, Zheng Y, Sehn LH, et al. Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia. J Clin Oncol. 2016;34:4194.
   PubMed Web of Science ®Google Scholar
• NCCN. NCCN Guidelines Version 3.2016: Non-Hodgkin's Lymphomas; 2016. Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp
   Google Scholar
• Ellin F, Landstrom J, Jerkeman M, et al. Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study. Blood. 2015;126:36–41.
   PubMed Web of Science ®Google Scholar
• Gambacorti Passerini C, Farina F, Stasia A, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst. 2014;106:djt378.
   PubMedGoogle Scholar
• Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190–2196.
   PubMed Web of Science ®Google Scholar
• Liedtke M, Hamlin PA, Moskowitz CH, et al. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol. 2006;17:909–913.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Dickinson M, Hofman MS, et al. Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy. Ann Hematol. 2014;93:1193–1200.
   PubMed Web of Science ®Google Scholar
• Tang T, Chen Z, Praditsuktavorn P, et al. Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2016;16:117–121.
   PubMed Web of Science ®Google Scholar
• Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med. 2009;169:2078–2086.
   PubMed Web of Science ®Google Scholar
• Chien SH, Liu CJ, Hu YW, et al. Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: a nationwide population-based study. Int J Cancer. 2015;137:658–665.
   PubMed Web of Science ®Google Scholar
• Thompson CA, Charlson ME, Schenkein E, et al. Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Ann Oncol. 2010;21:2262–2266.
   PubMed Web of Science ®Google Scholar
• Sibon D, Fournier M, Briere J, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. JCO. 2012;30:3939–3946.
   PubMed Web of Science ®Google Scholar